Additionally, in January 2025, sotorasib plus panitumumab was approved for metastatic KRAS G12C-mutated CRC, supported by findings from the CodeBreaK 300 trial (NCT05198934). The gene discussed is KRAS; the disease is colorectal carcinoma.